© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Phase 3 VESALIUS-CV Trial Demonstrates Evolocumab Reduces Cardiovascular Events in High-Risk Adults Without Prior Heart Attack or Stroke
October 02, 2025
Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.
10 Must-See Sessions for Primary Care Physicians at FMX 2025
October 02, 2025
Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.
Linus Health Will Highlight Digital Innovations in Early Detection of Cognitive Decline at FMX 2025
October 02, 2025
Linus Health will demonstrate advances in remote assessment platforms and digital biomarkers of cognitive health that can bring precision medicine to primary care.
Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults
October 02, 2025
Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.
FDA Grants Fast Track Designation to Anti-MTBR Tau Antibody BMS-986446 for Alzheimer Disease
October 01, 2025
The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154
October 01, 2025
Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.
Suboptimal Risk Factor Levels are Nearly Universal at Onset of CVD, Study of 10 Million Reveals
October 01, 2025
The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.
Cannabis Extract Provides LBP Relief Superior to Opioids Over 12 Months in Phase 3 Clinical Trial
October 01, 2025
Vertanical's VER-01 shows promise in reducing chronic low back pain, outperforming opioids and maintaining relief for over a year.
The End of Universal COVID-19 Vaccine Coverage Doesn't Mean the End of Payer Coverage, At Least Not for 2026: A Conversation with Kelly Moore, MD, MPH
September 30, 2025
Public health expert Kelly Moore, MD, MPH, president and CEO of immunize.org, says the news is good for now, but the uninsured could be at future risk.
Measles Outbreak Fails to Push MMR Rates to Herd Immunity Levels, Study Reveals
September 30, 2025
Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.